Congressional Medicare policy advisers on Friday unanimously endorsed Medicare Part B drug reimbursement changes that hospitals say would amplify the effect of Part B drug payment cuts for 340B hospitals in place since 2018.
The Medicare Payment Advisory Commission (MedPAC)
…
Prisons struggling with the high cost of treating inmates with viral illnesses such as hepatitis C and HIV can turn to the 340B program for relief, but participation is often tricky.
That was the takeaway of “Demystifying 340B for Correctional
…
The U.S. Health and Human Services Department (HHS) yesterday released the spring edition of its twice-annual public inventory of forthcoming regulatory actions. Although it was silent about the 340B program, 340B stakeholders shouldn’t breathe a sigh of relief yet.
Just
…
The American Hospital Association (AHA) yesterday asked U.S. Health and Human Services (HHS) Secretary Xavier Becerra to temporarily waive 340B program eligibility criteria for hospitals at risk of losing their 340B eligibility due to changes in payer mix caused by
…
The association for U.S. for-profit hospitals submitted a brief to the U.S. Supreme Court and released a study today arguing against reversing the nearly 30 percent cut in what Medicare pays many public and private nonprofit hospitals for physician-administered, 340B-purchased
…
Nine states are considering legislation to create boards to review prescription drug prices and intervene to lower them if drugs become too expensive or if their prices spike. Although the bills’ implications for the 340B program have not been fully
…
The second of four opportunities this year for covered entities to register themselves, their sites, and their contract pharmacies in the 340B program starts this Thursday, April 1 and ends on Thursday, April 15. New registrants can begin buying discounted
…
The manufacturer of Nulibry, a recently approved, first-of-its-kind injectable treatment for a very rare, often fatal genetic disorder that typically appears soon after birth, has posted details about the limited distribution network for the drug on the U.S.
…
The federal government on Tuesday declared 340B administrative dispute resolution (ADR) petitions by covered entities against drug manufacturers AstraZeneca, Eli Lilly, and Sanofi to be “complete,” a sign that claims against two of the three companies—AstraZeneca and Sanofi—are ready for
…
The U.S. Health and Human Services Department (HHS) announced late this morning that it will delay, from this coming Monday, March 22 until July 20, the effective date of a Trump administration rule to require health centers to provide insulin
…
×
*Sign up for news summaries and alerts from 340B Report